Dosing & monitoring

Epidyolex offers flexible dosing to help optimise treatment response for your patients. There is a recommended dosage range for maintenance dosing and new Epidyolex patients will need to undergo a titration to reach their maintenance dosage.¹

Recommended Epidyolex starting dosage and titrating for patients¹

Week 1	Recommended starting dosage 5 mg/kg/day (2.5 mg/kg twice daily)
Week 2	Recommended maintenance dosage 10 mg/kg/day (5 mg/kg twice daily)
Based on individual clinical response and tolerability	Dose increased to a maximum recommended dosage of 20 mg/kg/day (10 mg/kg twice daily)

vertical-header

1

bold

False

Based on individual clinical response and tolerability, dosage titrations should be increased in weekly increments of 2.5 mg/kg administered twice daily (5 mg/kg/day). Any dose increases above 10 mg/kg/day, to maximum recommended dose of 20 mg/kg/day, should be made considering individual benefit and risk and with adherence to the full monitoring schedule.

Epidyolex dose adjustment for special populations¹

Hepatic Impairment	Moderate	Severe
Starting Dosage	2.5 mg/kg/day (1.25 mg/kg twice daily)	1 mg/kg/day (0.5 mg/kg twice daily)
Maintenance Dosage	5 mg/kg/day (2.5 mg/kg twice daily)	2 mg/kg/day (1 mg/kg twice daily)
Maximum Dosage	10 mg/kg/day (5 mg/kg twice daily)	4 mg/kg/day* (2 mg/kg twice daily)

vertical-header

1

bold

False

* Higher doses of Epidyolex may be considered in patients with severe hepatic impairment where the potential benefits outweigh the risks.

Epidyolex does not require dose adjustment in patients with:¹

Mild hepatic impairment
Mild, moderate or severe renal impairment

Co-administration of Epidyolex with commonly prescribed anti-epileptic drugs (AEDs)¹

Epidyolex can interact with some commonly prescribed AEDs, which should be monitored and may require dose adjustment.

Clobazam

Interaction	Increase in both CBD and clobazam active metabolites
Adverse events	Increased incidence of somnolence and transaminase elevations vs. placebo
Dose adjustment	Consider reduction of Epidyolex or clobazam dose

horizontal-header

1

bold

False

Valproate

Interaction	No effect on CBD or its metabolites and no effect on valproic acid exposure
Adverse events	Increase in incidence of transaminase elevations, diarrhoea and events of decreased appetite
Dose adjustment	Discontinuation or reduction of valproate and/or Epidyolex* *If clinically significant increases of transaminases occur, CBD and/or concomitant valproate should be reduced or discontinued in all patients until a recovery of transaminase elevations are observed

horizontal-header

1

bold

False

Stiripentol

Interaction	Minor decrease in CBD active metabolite and increase in stiripentol levels
Adverse events	Clinical importance has not been studied. Patients should be closely monitored for adverse drug reactions.
Dose adjustment	N/A

horizontal-header

1

bold

False

Phenytoin

Interaction	Increase in phenytoin level
Adverse events	Assessed in vitro, not assessed in human clinical trials
Dose adjustment	Consider reduction of phenytoin dose

horizontal-header

1

bold

False

Lamotrigine

Interaction	Interaction unknown; lamotrigine levels may increase
Adverse events	Assessed in vitro, not assessed in human clinical trials
Dose adjustment	N/A

horizontal-header

1

bold

False

CBD, cannabidiol

Co-administration with other medicines

CYP1A2 substrates

(e.g. caffeine)

Interaction	Increase in substrate levels
Adverse events	Clinical importance has not been studied. Patients should be closely monitored for adverse drug reactions
Dose adjustment	N/A

horizontal-header

1

bold

False

CYP3A4 or CYP2C19 inducers

(e.g. carbamazepine, St. John’s wort and rifampicin)

Interaction	Decrease in CBD and its active metabolites
Adverse events	Reduced effectiveness of CBD
Dose adjustment	Consider dose increase of Epidyolex

horizontal-header

1

bold

False

UGT2B7 substrates

(e.g. lamotrigine, morphine and lorazepam)

Interaction	Increase in substrate levels
Adverse events	Assessed in vitro, not assessed in human clinical trials
Dose adjustment	Consider reduction of substrate dose

horizontal-header

1

bold

False

CYP2C19 substrates

(e.g. omeprazole)

Interaction	Increase in substrate levels
Adverse events	Assessed in vitro, not assessed in human clinical trials
Dose adjustment	Consider reduction of substrate dose

horizontal-header

1

bold

False

Monitoring¹

Prior to starting treatment with Epidyolex, obtain serum transaminases (ALT and AST) and total bilirubin levels.

Routine monitoring schedule

Pre-treatment

Test 1

Month 1

Test 2

Month 3

Test 3

Month 6

Test 4

Ongoing

As clinically indicated

Upon changes in Epidyolex dose above 10 mg/kg/day or changes in medicinal products that are known to impact the liver, this monitoring schedule should be restarted.

Patients with identified baseline elevations of ALT or AST and patients who are taking valproate are recommended to undergo intensified monitoring:

Intensified monitoring schedule

Prior to treatment

Test 1

2 weeks

Test 2

Month 1

Test 3

Month 2

Test 4

Month 3

Test 5

Month 6

Test 6

Ongoing

As clinically indicated

Upon changes in cannabidiol dose above 10 mg/kg/day or changes in medicinal products that are known to impact the liver, this monitoring schedule should be restarted.

If a patient develops clinical signs and symptoms suggestive of hepatic dysfunction, serum transaminases and total bilirubin should be promptly measured and treatment with Epidyolex should be interrupted or discontinued, as appropriate.

AED safety information ¹

Somnolence

Monitor patients for somnolence and sedation and advise patients not to drive or operate machinery until they have gained sufficient experience on Epidyolex to gauge whether it adversely affects their ability to drive or operate machinery.
Suicidal behaviour and ideation

Suicidal behaviour and ideation have been reported in patients treated with AEDs in several indications. Patients should be monitored for signs of suicidal behaviour and ideation and appropriate treatment should be considered. Patients and caregivers should be advised to seek medical advice should any signs of suicidal behaviour and ideation emerge.
Increased seizure frequency

As with other AEDs, a clinically relevant increase in seizure frequency may occur during treatment with Epidyolex, which may require adjustment in dose of Epidyolex and/or concomitant AEDs, or discontinuation of Epidyolex, should the benefit risk be negative.

Receive promotional communications and notifications about open-label extension data, our latest conference activity, key opinions from leading researchers and prescribers in cannabinoid therapy.

First Name

Last Name

Email(optional) Why do I need to provide my email address?

Address(optional) Why do I need to provide my address?

Phone(optional) Why do I need to provide my phone number?

Professional Role(optional)

Area of expertise(optional)

Company or Institution Why do I need to provide my company?

Country

Privacy policy
Consent for educational information and communications and notification of the collection and processing of personal data for this purpose
GW Pharma Limited (“GW”) is a UK company which is part of the UK-based GW Pharmaceuticals group that develops and markets cannabinoid-based medicines. We respect individuals’ rights in relation to the privacy and the confidentiality of their personal data. We only collect and use the personal data necessary to provide you with educational information and communications, as described below. The data controller of the personal data we collect for these purposes is GW Pharma Limited (company number 03074998) with the address Sovereign House, Vision Park, Chivers Way, Histon, Cambridge CB24 9BZ, United Kingdom.

Personal data that we collect about you and why
In addition to collecting your personal data directly from you, we may also collect personal data about you from a variety of sources including from publicly available sources, online and other databases and websites, and other documents or forms that you provide in order to participate in GW-sponsored or supported initiatives, such as GW-sponsored medical education, research and development activities, or in other contexts.

GW may collect and use some or all of the following categories of personal data about you:
- personal details such as your name, age, gender and contact details;
- professional details such as your place of practice, job title, the medical field in which you are active, your professional qualifications and scientific activities (such as previous clinical trial experience, and participation in past or pending research studies with GW and other companies), publication of academic or scientific research and articles, and membership in associations and boards; and
- details of interactions with us, such as what kind of meetings we have held, topics discussed, your knowledge of and questions you have had on our business and products, what kind of material we have displayed to you and any feedback that you have provided, as well as your opinions and routines on prescribing, routines regarding your patients and diagnosis,
We process this information in our customer databases for the purpose of providing educational information and communications, and managing our relationship with you, including planning potential collaboration, contact, and helping ensure that we provide you with information that is relevant given your expertise, interests and preferences. The legal basis for this processing is our legitimate interest in maintaining a relationship with you and to provide you with the information you have requested.

Sharing your personal data
GW may share your personal data with others, from time to time, in connection with the purpose described in this notice. In particular, we may make your personal data available to:
- other companies within the GW Pharmaceuticals group;
- third party companies with whom we may partner in connection with proposed or actual GW projects such as commercialisation, medical communication, market research, creative agency, market access;
- third party companies that supply goods or services to GW such as legal counsel, auditors and IT service suppliers;
- other third parties pursuant to a court order, to protect the interests of GW, or where otherwise required by law or legal process; and actual or prospective purchasers of GW businesses in the event of a sale, merger or acquisition
Sharing your personal data as described above may involve transferring it to countries, including countries outside of the EU/EEA, whose data protection and privacy laws may not be equivalent to, or as protective as, those which exist in your country of residence. However, in accordance with applicable law, GW implements measures such as standard data protection clauses to ensure that any transferred personal data remains protected and secure.

Securing and retaining your personal data
GW will take appropriate technical and organisational security measures to protect your personal data consistent with applicable privacy and data security laws. When GW retains a third-party service provider, that provider will be carefully selected and required to use appropriate measures to protect the confidentiality and security of personal data. GW retains your personal data only for as long as we continue to have a relationship with you, unless a longer retention period is required or permitted by law.

Your rights
You may contact GW to request access to personal data that we process about you and that we correct inaccurate data and complete any incomplete data. In accordance with the conditions and requirements of applicable law, you may object to our processing your personal data and request that we erase personal data about you, restrict processing of such data, and transmit your personal data to you or another data controller. Should you wish to exercise these rights or if you have any questions regarding this notice or prefer that GW not contact you again, please let GW know by contacting us at info@gwpharm.com. You may lodge a complaint with a supervisory authority if you consider that our processing of your personal data infringes applicable law.

Your consent to receive educational information and marketing communications

Applicable laws may require GW to obtain your specific consent in order to contact you by email or other electronic means, and by non-electronic means, with educational information and marketing communications about GW Pharmaceuticals and its products that we feel may be of interest to you.

Providing your consent to GW Pharmaceuticals sending you educational information and marketing communications is voluntary. You may withdraw your consent by unsubscribing. Should you withdraw your consent, it may prevent GW Pharmaceuticals from sending you further information or communications, although GW Pharmaceuticals may be required or entitled to continue to process your personal data in order to comply with its legal and regulatory obligations and to protect its legal rights and interests, but at all times such processing will be in accordance with the Privacy Policy.

To provide your consent to receive educational information and marketing communications from GW Pharmaceuticals, please provide the following details and indicate your consent by ticking the boxes below:

I confirm I have read, understood and agree to marketing communications and educational materials from GW Pharmaceuticals in line with the GW Pharmaceuticals terms of service and privacy policy as highlighted.

I have read and understood the GW Pharmaceuticals privacy policy.

By providing your information, you agree to the GW Pharmaceuticals terms of service and privacy policy.

Mail confirmed(optional)

References

1. Epidyolex Summary of Product Characteristics (Date accessed: 03/09/2020).

Dosing & monitoring

Co-administration of Epidyolex with commonly prescribed anti-epileptic drugs (AEDs)1

Monitoring1

AED safety information 1

Sign up and stay up to date

Co-administration of Epidyolex with commonly prescribed anti-epileptic drugs (AEDs)¹

Monitoring¹

AED safety information ¹